Cutaneous Side Effects of Modern Targeted Therapy and Immunotherapy in Patients with Dermatological Malignancies

The advent of immunotherapy and targeted therapies in treating dermatological malignancies has dramatically changed the landscape of dermato-oncology in recent years. Their superior efficacy compared to previous therapeutic options, such as chemotherapy, has resulted in their use in treating devasta...

Full description

Saved in:
Bibliographic Details
Published inCancers Vol. 15; no. 12; p. 3126
Main Authors Plachouri, Kerasia-Maria, Florou, Vaia, Georgiou, Vasileios, Georgiou, Sophia
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 09.06.2023
MDPI
Subjects
Analysis
Antimitotic agents
Antineoplastic agents
Cancer
Care and treatment
Cell growth
Chemotherapy
Complications and side effects
Dermatitis
Development and progression
Immune checkpoint inhibitors
Immunology
Immunotherapy
Kinases
Malignancy
Melanoma
Metastases
Mutation
Oncology, Experimental
Patients
Proteins
Pruritus
Psoriasis
Quality of life
Review
Side effects
Skin
Skin cancer
Squamous cell carcinoma
Toxicity
targeted therapy
basal cell carcinoma
melanoma
cutaneous side effects
immune checkpoint inhibitors
squamous cell carcinoma
Online AccessGet full text

Cover

More Information
Summary:The advent of immunotherapy and targeted therapies in treating dermatological malignancies has dramatically changed the landscape of dermato-oncology in recent years. Their superior efficacy compared to previous therapeutic options, such as chemotherapy, has resulted in their use in treating devastating malignancies, such as melanoma or unresectable/metastatic basal cell and squamous cell carcinoma. Skin toxicity is a critical safety consideration, among other adverse reactions, that can occur under treatment with these agents. This article aims to summarize the cutaneous side effects of immune checkpoint inhibitors and targeted dermato-oncological therapies. Although the skin side effects of these agents are primarily mild, they can occasionally affect the decision for treatment continuation and the quality of life of the affected patients. Therefore, physicians must be acquainted with the specific cutaneous toxicity profile of such treatments to mitigate their impact on the patients and optimize the overall outcome of dermato-oncological therapy.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers15123126